Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Adam S. Grossman, President and CEO of ADMA Biologics, INC. (NASDAQ:ADMA), sold 21,000 shares of common stock on October 24, 2025, at a price of $16.0, for a total of $336,000. The transaction comes as ADMA maintains a strong financial position, with InvestingPro data showing impressive revenue growth of 44% and a healthy current ratio of 5.3x.
On the same day, Grossman also exercised options to acquire 15,000 shares of ADMA Biologics common stock at $5.4, for a total value of $81,000.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on December 5, 2024. Following these transactions, Grossman directly owns 2,019,850 shares of ADMA Biologics. He also indirectly owns 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC.
In other recent news, ADMA Biologics reported its second-quarter 2025 earnings, which did not meet analyst expectations. The company’s earnings per share (EPS) came in at $0.14, slightly below the forecasted $0.15. Additionally, ADMA Biologics reported revenues of $122 million, missing the anticipated $124.13 million. These earnings and revenue figures are crucial for investors as they assess the company’s financial performance. Despite these results, there was no mention of any changes in analyst ratings or significant mergers involving ADMA Biologics. Investors will likely continue to monitor the company’s developments closely. These updates provide insight into ADMA Biologics’ recent financial activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.